Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis B

Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis B - Prospective observational study of PEGASYS for hepatitis B

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008045

Enrollment

400

Registered

2012-05-29

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic active hepatitis B (CHB)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with HBeAg positive or HBeAg negative chronic active hepatitis B

Exclusion criteria

Exclusion criteria: chronic active hepatitis B patients without HBeAg data

Design outcomes

Primary

Measure	Time frame
virological and biochemical efficacy at 24 weeks (6 months) after treatment	—

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co., Ltd. Real World Data Science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results